Log in to search using one of your social media accounts:

 

Less Is More: Patients With Colon Cancer Get a Chemo Break Less Is More: Patients With Colon Cancer Get a Chemo Break
Data show that 3 months of oxaliplatin-based chemotherapy is as effective as 6 months but has less toxicity, good news for patients with colon cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 4, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Will Adjuvant Oxaliplatin Data Change Practice in CRC? Will Adjuvant Oxaliplatin Data Change Practice in CRC?
Dr John Marshall previews the GI cancer studies being presented at ASCO with his picks for the ones to watch, and predicts that a plenary presentation may be practice-changing.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Adjuvant GEMOX Did Not Improve RFS for Localized Biliary Tract Cancer
Adjuvant chemotherapy for biliary tract cancer using GEMOX (gemcitabine/oxaliplatin) was feasible, but did not result in an improved recurrence-free survival or quality of life compared with surveillance in the phase III PRODIGE 12-ACCORD 18 trial. (Source: CancerNetwork)
Source: CancerNetwork - January 23, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Liver, Gallbladder, and Biliary Tract Cancers News Source Type: news

Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer
A 44-year-old patient with a history of stage IIB colorectal cancer at the hepatic flexure, invading the duodenum and pancreas, was initially diagnosed in September 2005 and received modified Whipple surgery and 8 cycles of adjuvant chemotherapy with capecitabine and oxaliplatin every 3 weeks. (Source: CancerNetwork)
Source: CancerNetwork - November 15, 2016 Category: Cancer & Oncology Authors: Henning Schade, MD Lindsey Davis, MD Peter Kabos, MD Tags: Case Studies Colorectal Cancer Oncology Journal Source Type: news

High-capacity nanoparticle holds potential for targeted cancer therapies
Image: Jeremiah Johnson Chemists from the Mass. Institute of Technology developed a nanoparticle that they can pack with 3 or more drugs to create custom combination therapies for cancer, according to a study published this week in the Journal of the American Chemical Society. The team also revealed that cisplatin, a powerful anti-cancer drug, doesn’t work using the same DNA-damaging mechanism when delivered via nanoparticle compared to traditional methods. The team uses a unique nanoparticle production method, which they 1st reported in 2014. Instead of trying to load the drugs onto nanoparticles that are already bu...
Source: Mass Device - September 15, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Oncology Research & Development Mass. Institute of Technology Source Type: news

Colon Cancer With Microsatellite Instability: Adjuvant Chemo Colon Cancer With Microsatellite Instability: Adjuvant Chemo
Is deficient mismatch repair colon cancer resistant to adjuvant 5-fluorouracil plus oxaliplatin?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Molecule prevents effect of chemotherapy
(Aarhus University Hospital) For the last three years the research team has been working on the development of a so-called biomarker to predict treatment effectiveness. Now the researchers found a molecule which is closely associated with the effect of Oxaliplatin treatment, an anti-cancer drug widely used in the treatment of colorectal cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 16, 2016 Category: Cancer & Oncology Source Type: news

Rectal Cancer: Oxaliplatin-based Preoperative Chemoradiation Rectal Cancer: Oxaliplatin-based Preoperative Chemoradiation
Does preoperative 5 x 5 Gy irradiation and FOLFOX4 consolidation chemotherapy improve outcomes in rectal cancer? Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 29, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Oxaliplatin-Based Adjuvant Chemo for Stage III MMR CRC Oxaliplatin-Based Adjuvant Chemo for Stage III MMR CRC
Oxaliplatin-based adjuvant chemotherapy was be better than surgery alone for patients with stage 3 colorectal cancer with mutations in DNA mismatch repair genes. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 22, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/minOxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min
A study finds that oxaliplatin can be infused safely at a faster rate than previously determined and hopefully this will result in less overall treatment time and improved patient satisfaction. Journal of Oncology Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 9, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Researchers Identify Best Drug Therapy for Rare, Aggressive, Pancreatic Cancer
JACKSONVILLE, Fla. — Each year, about 200 to 400 Americans develop pancreatic acinar cell carcinoma, a rare form of pancreatic cancer that has no effective standard of care. A study involving researchers on Mayo Clinic’s Florida and Rochester campuses has found that the chemotherapy drug oxaliplatin is effective in stopping the growth of this cancer. [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - May 25, 2016 Category: Research Source Type: news

Debiopharm International SA Has Won Its Patent Infringement Suit for Elplat(R) Against Nippon Kayaku Co., Ltd.
LAUSANNE, Switzerland, March 4, 2016 -- (Healthcare Sales & Marketing Network) -- Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company today announces that the Tokyo District Court granted Deb... Biopharmaceuticals, Generics, Oncology, LitigationDebiopharm Group, Elplat, Oxaliplatin, Nippon Kayaku Co (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 4, 2016 Category: Pharmaceuticals Source Type: news

New method of drug delivery may be safer and more effective against pancreatic cancer
The overall five-year survival rate for people with pancreatic cancer is just 6 percent, and there is an urgent need for new treatment options. More than 80 percent of pancreatic cancer diagnoses occur too late for surgery, making chemotherapy the only possible treatment. Scientists from the California NanoSystems Institute at UCLA and UCLA’s Jonsson Comprehensive Cancer Center have developed a delivery system for one chemotherapy drug that greatly reduces the occurrence of serious side effects while enhancing the drug’s effectiveness against pancreatic cancer. The approach uses mesoporous silica nanoparticles ...
Source: UCLA Newsroom: Health Sciences - March 2, 2016 Category: Universities & Medical Training Source Type: news

Success of Platinum Desensitization 'Depends on the Agent'Success of Platinum Desensitization 'Depends on the Agent'
Cancer patients receiving oxaliplatin are more likely to experience hypersensitivity reactions during desensitization than those given carboplatin. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 2, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Evaluation of NK1 antagonists for emesis prevention in oxaliplatin chemo: SENRI trial
The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, results of a new study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 1, 2015 Category: Science Source Type: news

Evaluation of NK1 antagonists for emesis prevention in oxaliplatin chemo: SENRI trial
(European Society for Medical Oncology) The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, results of a Japanese study presented today at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona reveal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 1, 2015 Category: Global & Universal Source Type: news

New prostate cancer treatment has promising results in mice
Conclusion This study has built on the findings of previous research that has suggested B immune cells could have a role in making prostate tumours resistant to chemotherapy. This mouse study further investigated this by looking at different ways to suppress these B cells, using immune therapy or genetic techniques. It found that once these B cells were blocked or removed, chemotherapy was able to attack and destroy aggressive prostate cancer cells in mice. The potential for a new chemoimmunotherapy treatment approach for cancer is promising. However, the study is still at a very early stage. While mice studies can give an...
Source: NHS News Feed - April 30, 2015 Category: Consumer Health News Tags: Cancer Medication Source Type: news

New drug helps achieve almost complete prostate cancer remission in mice 
Scientists at the University of California at San Diego used the drug oxaliplatin to fire up cancer-killing immune cells in mice. There are currently few options for men who have aggressive prostate cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - April 30, 2015 Category: Consumer Health News Source Type: news

No Adjuvant Oxaliplatin for Elderly CRC PatientsNo Adjuvant Oxaliplatin for Elderly CRC Patients
Consensus guidelines offer distinct recommendations for adjuvant and palliative treatments in elderly patients with colorectal cancer, as discussed by Dr David Kerr. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2015 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Cost of cancer drugs varies widely based on who;s paying
Uninsured cancer patients are asked to pay anywhere from two to 43 times what Medicare would pay for chemotherapy drugs, according to a new study. Uninsured patients who did not negotiate billed amounts for chemo drugs could expect to pay $6,711 for an infusion of the colorectal cancer drug oxaliplatin. However, Medicare and private health plans only pay $3,090 and $3,616 for the same drug, respectively. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 7, 2015 Category: Science Source Type: news

Second-line Oxaliplatin Benefits Pancreatic Cancer PatientsSecond-line Oxaliplatin Benefits Pancreatic Cancer Patients
Dr Alok Khorana reports on the CONKO study, which shows that patients with pancreatic cancer who receive gemcitabine in first-line therapy benefit from second-line oxaliplatin-based therapy. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 26, 2015 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

More Drugs, Better Survival in Metastatic Colon Cancer
(MedPage Today) -- Addition of oxaliplatin to FOLFIRI and bevacizumab doubled 5-year survival. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 13, 2015 Category: Primary Care Source Type: news

Secondary analysis of RTOG 0247 demonstrates favorable OS rates for rectal cancer patients
Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 9, 2015 Category: Science Source Type: news

Secondary analysis of RTOG 0247 demonstrates favorable OS rates for rectal cancer patients
(American Society for Radiation Oncology) Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a study published in the January 1, 2015 issue of the International Journal of Radiation Oncology * Biology * Physics, the official scientific journal of the American Society for Radiation Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 9, 2015 Category: Cancer & Oncology Source Type: news

Sanofi introduces authorised generic version of Eloxatin
Sanofi US has introduced an authorised generic version of Eloxatin (oxaliplatin injection), a platinum-based drug used in combination with infusional 5-fluorouracil / leucovorin. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 13, 2014 Category: Pharmaceuticals Source Type: news

Dorsal Sural Nerve Test Sensitive to Oxaliplatin NeuropathyDorsal Sural Nerve Test Sensitive to Oxaliplatin Neuropathy
Dorsal sural nerve conduction testing is a moderately sensitive and very specific test for early detection of oxaliplatin-induced peripheral neuropathy and beats sural nerve testing. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 13, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Again, Oxaliplatin Is Toxic and No Benefit in Rectal CancerAgain, Oxaliplatin Is Toxic and No Benefit in Rectal Cancer
Yet another rectal cancer study has found that the addition of oxaliplatin to capecitabine chemoradiation in locally advanced disease gives no short-term postoperative benefit and increases toxicity. Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - April 7, 2014 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Mangafodipir treatment for oxaliplatin-associated neuropathy
An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 31, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

IV Calcium, Magnesium Don't Prevent Oxaliplatin NeurotoxicityIV Calcium, Magnesium Don't Prevent Oxaliplatin Neurotoxicity
Infusions of calcium and magnesium (CaMg) do not prevent oxaliplatin-induced sensory neurotoxicity, according to a new trial. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Evaluation of mangafodipir treatment for oxaliplatin-associated neuropathy
(Journal of Clinical Investigation) In this issue of the Journal of Clinical Investigation, Frédéric Batteux and colleagues at the Laboratoire d'Immunologie evaluated use of the MRI contrast agent mangafodipir, which has antioxidant properties, for relief of oxaliplatin-associated neuropathies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 20, 2013 Category: Global & Universal Source Type: news

JCI early table of contents for Dec. 20, 2013
(Journal of Clinical Investigation) This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online, Dec. 20, 2013 in the JCI: "Fungal surface protein promotes host cell invasion," "Angiogenic factor secretion by melanocytes associated with pigmentation level," "Nonsense suppression drug restores function in a mouse model of aniridia," "Dysfunctional TGF-beta signaling contributes to Loeys-Dietz syndrome-associated aortic aneurysm," "Evaluation of mangafodipir treatment for oxaliplatin-associated neuropathy,"...
Source: EurekAlert! - Cancer - December 20, 2013 Category: Cancer & Oncology Source Type: news

Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer
(European Organisation for Research and Treatment of Cancer) Long term results of the randomized phase III EORTC intergroup trial 40983 were recently reported in The Lancet Oncology. The observed 4.1 percent difference in overall survival at five years for patients with initially resectable liver metastases from colorectal cancer was not significant for perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) compared with surgery alone. The authors conclude that perioperative chemotherapy with FOLFOX4 should remain the reference treatment for this population of patients. (Source: EurekAlert! -...
Source: EurekAlert! - Medicine and Health - November 6, 2013 Category: Global & Universal Source Type: news

Indication Of Minor Added Benefit For Aflibercept In Colorectal Cancer
Indication of considerable added benefit for overall survival / indications of greater harm from side effects The drug aflibercept (trade name: Zaltrap) has been approved in Germany since February 2013 in combination with a certain chemotherapy for adults with metastatic colorectal cancer in whom chemotherapy with oxaliplatin could not stop the disease from progressing... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 15, 2013 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news

Adjuvant Chemo Boosts Survival in Advanced Stomach CancerAdjuvant Chemo Boosts Survival in Advanced Stomach Cancer
Mature data from a phase 3 trial confirm that capecitabine plus oxaliplatin after gastrectomy yields a significant survival advantage over surgery alone. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 9, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study confirms adding chemotherapy to surgery improves survival in advanced gastric cancer
(European Society for Medical Oncology) At the meeting Prof Sung Hoon Noh, a gastric surgeon from Yonsei University College of Medicine, Korea, presented 5-year follow-up from the phase III CLASSIC trial, which added combination chemotherapy to a standard surgical procedure called D2 gastrectomy. The chemotherapy regimen studied in the trial is called XELOX, which is a combination of the drugs capecitabine and oxaliplatin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 3, 2013 Category: Global & Universal Source Type: news

Stop Using Calcium and Magnesium With Oxaliplatin Stop Using Calcium and Magnesium With Oxaliplatin
New results have led to call for stopping the practice of administering intravenous calcium and magnesium to reduce oxaliplatin neurotoxicity. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 4, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Adding Oxaliplatin to Radiotherapy in Nasopharyngeal CancerAdding Oxaliplatin to Radiotherapy in Nasopharyngeal Cancer
Adding oxaliplatin to radiotherapy (RT) for locoregionally advanced nasopharyngeal carcinoma appears to have lasting survival benefits, according to Chinese researchers. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 27, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ZALTRAP® (Aflibercept) Approved In The EU For Patients With Previously Treated Metastatic Colorectal Cancer
First and only agent to statistically significantly improve survival in combination with FOLFIRI chemotherapy after an oxaliplatin regimenSanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 8, 2013 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news

ZALTRAP® approved in the EU for metastatic colorectal cancer
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced that the European Commission (EC) granted marketing authorisation in the European Union for ZALTRAP® (aflibercept) 25mg/ml concentrate for solution for infusion in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen. (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 6, 2013 Category: Drugs & Pharmacology Source Type: news

EMA grants marketing authorisation of aflibercept (ZaltrapT) for previously treated metastatic colorectal cancer
Source: BioSpace Area: News The European Commission (EC) has granted marketing authorisation for aflibercept (ZaltrapT) for use in combination with irinotecan/ 5-fluorouracil/ folinic acid (FOLFIRI) chemotherapy for the treatment of adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.   This decision was based on the efficacy and safety results of the multinational, phase III randomised controlled VELOUR trial (n=1,226). The study showed that in patients previously treated with an oxaliplatin containing regimen, adding aflibercept to FOLF...
Source: NeLM - News - February 6, 2013 Category: Drugs & Pharmacology Source Type: news

FDA Approves Bevacizumab for Second-Line Combinations
Bevacizumab is now approved by the Food and Drug Administration for use in combination with fluoropyrimidine-irinotecan-based or fluoropyrimidine-oxaliplatin-based chemotherapy for metastatic colorectal... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 29, 2013 Category: Cancer & Oncology Source Type: news

FDA approves use of bevacizumab for patients whose colorectal cancer has worsened despite previous treatment with the drug
Source: Reuters Area: News The FDA has approved the use of bevacizumab for patients whose colorectal cancer has worsened despite previous treatment with the drug. The new use will allow patients first treated with bevacizumab plus chemotherapy to be treated again with it in combination with a different chemotherapy regimen.   The clinical data to support this indication come from the phase 3 ML18147 study in 820 patients with unresectable metastatic colorectal cancer progressing up to 3 months after discontinuing first-line bevacizumab plus chemotherapy. They were randomised to second-line chemotherapy with (n= ...
Source: NeLM - News - January 25, 2013 Category: Drugs & Pharmacology Source Type: news

FDA approves new use of Avastin plus chemotherapy for people with metastatic colorectal cancer
Roche today announced that the US Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC). The new indication will allow people who received Avastin plus an irinotecan or oxaliplatin containing chemotherapy as an initial treatment (first-line) for mCRC to continue to receive Avastin plus a different irinotecan or oxaliplatin containing chemotherapy after their cancer worsens (second-line treatment). (Source: Roche Media News)
Source: Roche Media News - January 24, 2013 Category: Pharmaceuticals Source Type: news

FDA approves new use of Avastin plus chemotherapy for people with metastatic colorectal cancer
Roche today announced that the US Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC). The new indication will allow people who received Avastin plus an irinotecan or oxaliplatin containing chemotherapy as an initial treatment (first-line) for mCRC to continue to receive Avastin plus a different irinotecan or oxaliplatin containing chemotherapy after their cancer worsens (second-line treatment). (Source: Roche Investor Update)
Source: Roche Investor Update - January 24, 2013 Category: Pharmaceuticals Source Type: news

FDA approves colon cancer drug combo
WASHINGTON, Jan. 23 (UPI) -- The U.S. Food and Drug Administration says it approved a new use of Avastin in combination with oxaliplatin chemotherapy for those colorectal cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 24, 2013 Category: Consumer Health News Source Type: news

Oxaliplatin and bevacizumab disappoint for rectal cancer
The addition of bevacizumab and oxaliplatin to standard neoadjuvant chemoradiotherapy does not enhance clinical response rates in rectal cancer, show phase II study results. (Source: MedWire News - Gastroenterology)
Source: MedWire News - Gastroenterology - January 10, 2013 Category: Gastroenterology Source Type: news

Oxaliplatin and bevacizumab disappoint for rectal cancer
The addition of bevacizumab and oxaliplatin to standard neoadjuvant chemoradiotherapy does not enhance clinical response rates in rectal cancer, show phase II study results. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 10, 2013 Category: Cancer & Oncology Source Type: news

New NCCN Treatment Recommendations for Colon and Rectal Cancers
ROCKLEDGE, PA, February 4, 2003 - The National Comprehensive Cancer Network (NCCN) announces the publication of the first of the 2003 NCCN Clinical Practice Guidelines in Oncology, the Colon and Rectal Cancer Treatment Guidelines, in the January edition of JNCCN, the official journal of the NCCN. These updated guidelines contain new treatment recommendations regarding the use of the recently approved agent, oxaliplatin, and of radiation therapy in Stage II, III, and IV disease. “The inclusi... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - February 4, 2003 Category: Cancer & Oncology Source Type: news